Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

Gastroenterology
Guruprasad P AithalJonathan Webber

Abstract

Nonalcoholic steatohepatitis (NASH) is a leading cause of chronic liver disease for which there is limited therapy available. Insulin sensitizing, anti-inflammatory, and antifibrotic properties of thiazolidinediones support their use in treating NASH. We have evaluated pioglitazone in the treatment of nondiabetic patients with NASH. We randomized 74 nondiabetic patients (45 men; median age, 54 y) with histologically proven NASH to 12 months of standard diet, exercise, and either placebo or pioglitazone (30 mg/day). Sixty-one patients (30 placebo, 31 pioglitazone) had liver biopsies both at the beginning and the end of the study. Compared with placebo, pioglitazone therapy was associated with an increase in weight (mean change, -0.55 vs +2.77 kg; P = .04) and a reduction in glucose (+0.4 vs -0.1 mmol/L; P = .02), HbA1c (+0.16% vs -0.18%; P = .006), insulin C peptide level (+42 vs -78 pmol/L; P = .02), alanine aminotransferase level (-10.9 vs -36.2 u/L; P = .009), gamma-glutamyltransferase level (-9.4 vs -41.2 u/L; P = .002), and ferritin (-11.3 vs -90.5 microg/L; P = .01). Histologic features including hepatocellular injury (P = .005), Mallory-Denk bodies (P = .004), and fibrosis (P = .05) were reduced in patients treated with p...Continue Reading

Citations

Jun 24, 2010·The Proceedings of the Nutrition Society·Jeremy F L CobboldSimon D Taylor-Robinson
Feb 25, 2010·International Journal of Obesity : Journal of the International Association for the Study of Obesity·G A GarinisA Belfiore
Oct 16, 2013·Nature Reviews. Gastroenterology & Hepatology·Vlad Ratziu
Dec 7, 2010·Antioxidants & Redox Signaling·E Matthew MorrisJamal A Ibdah
Dec 5, 2012·International Journal of Hepatology·Marilena DurazzoSimona Bo
Dec 24, 2011·Experimental Diabetes Research·Angela MazzaAntonino Belfiore
Jan 11, 2013·International Journal of Hepatology·Kei Nakajima
May 3, 2013·The Journal of Clinical Investigation·Detlef Schuppan, Yong Ook Kim
Jul 19, 2011·Therapeutic Advances in Gastroenterology·Lisa B Van Wagner, Mary E Rinella
Sep 17, 2011·Therapeutic Advances in Gastroenterology·Raluca PaisVlad Ratziu
Jun 1, 2010·Therapeutic Advances in Endocrinology and Metabolism·Sanjeev R Mehta
Nov 14, 2012·Therapeutic Advances in Endocrinology and Metabolism·Romina LomonacoKenneth Cusi
Dec 17, 2008·Journal of Lipid Research·Sandra K Erickson
Aug 16, 2012·Endocrine Journal·Toshinari TakamuraShuichi Kaneko
May 19, 2010·Biomarkers in Medicine·Vlad RatziuThierry Poynard
Nov 23, 2013·International Journal of Molecular Sciences·Barbara FruciAntonino Belfiore
Nov 6, 2009·World Journal of Gastroenterology : WJG·Mitsuteru KitadeHiroshi Fukui
Jan 1, 2010·Clinical Medicine Insights. Endocrinology and Diabetes·Cyrus V Desouza, Vijay Shivaswamy
Oct 1, 2011·Experimental Diabetes Research·Erifili HatziagelakiGeorge Dimitriadis
Feb 28, 2009·Women's Health·Ayako Suzuki, Manal F Abdelmalek
Nov 17, 2009·QJM : Monthly Journal of the Association of Physicians·J K DowmanP N Newsome
Dec 4, 2009·QJM : Monthly Journal of the Association of Physicians·E Erdmann, R Wilcox
Apr 24, 2009·Seminars in Liver Disease·Wing-Kin SynAnna Mae Diehl
Aug 31, 2011·Critical Reviews in Clinical Laboratory Sciences·Briohny W Smith, Leon A Adams
Oct 19, 2011·The Journal of Cell Biology·Natasha T SniderM Bishr Omary
Dec 8, 2015·Expert Review of Gastroenterology & Hepatology·Paola DongiovanniLuca Valenti
Nov 3, 2011·Expert Opinion on Pharmacotherapy·Simona MoscatielloGiulio Marchesini
Feb 27, 2015·Expert Review of Gastroenterology & Hepatology·Amanda Tamar SchneierDouglas T Dieterich
Mar 29, 2014·Expert Review of Gastroenterology & Hepatology·Mariana Verdelho Machado, Helena Cortez-Pinto
Jul 16, 2013·Expert Opinion on Emerging Drugs·Wataru TomenoAtsushi Nakajima
Mar 4, 2011·Expert Opinion on Drug Safety·Keith G Tolman
Jun 7, 2011·Expert Opinion on Pharmacotherapy·Claudia Della CorteValerio Nobili
Feb 24, 2010·Expert Opinion on Drug Safety·Priya Shah, Sunder Mudaliar
Mar 24, 2016·Gastroenterology Research and Practice·Newaz HossainSmruti R Mohanty
Mar 5, 2016·Digestive Diseases and Sciences·Kathleen E Corey, Mary E Rinella
Jan 29, 2011·Journal of Obesity·W K KarczJ M Grueneberger
Nov 6, 2014·Oxidative Medicine and Cellular Longevity·Aaron M GusdonShen Qu
Apr 14, 2015·Gastroenterology Research and Practice·S GittoP Andreone

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenocortical Carcinoma

Hepatocellular carcinoma is the most common type of primary liver cancer and frequently occurs in individuals with chronic liver diseases like cirrhosis. Here is the latest research.

Carcinoma, Lobular

Lobular carcinoma is an invasive type of breast cancer in which lobules, areas of the breast that produce milk, undergo malignant transformation. Here is the latest research.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis